



medicines
patent
pool



THE MEDICINES PATENT POOL

EXPANDING ACCESS TO PUBLIC HEALTH



medicines
patent
pool



IMPLEMENTATION OF DACLATASVIR LICENCE


Development Report
2017-March 2021

7 daclatasvir sublicensee agreements

DACLATASVIR



DAC 30mg & 60mg: FORMULATION DEVELOPMENT TIMELINES



 Companies approved

Note: Each triangle represents a manufacturer and timelines represent date of filing

**4 MPP LICENSEES HAVE DEVELOPED DAC 30/60 MG AND
ARE READY TO COMMERCIALIZE THE PRODUCT**

Licensees Approved: Cipla, Hetero, Laurus, Mylan (60mg)

DAC 30mg & 60mg: COUNTRY-WISE FILING STATUS

Generic DAC has been filed in **52** countries, of which approval has been received in **34** countries
Filings have occurred where **74%** PLHCV[^] reside in the licensed territory[#]

APPROVED (34) 67% PLHCV

Benin	Guyana	Pakistan
Burkina Faso	India	Philippines
Cambodia	Indonesia	Tanzania
Cameroon	Kazakhstan	Turkmenistan
Chad	Kyrgyzstan	Uganda
Congo, Dem. Rep.	Liberia	Ukraine
Congo, Rep.	Malawi	Uzbekistan
Côte d'Ivoire	Malaysia	Vietnam
Dominican Republic	Mongolia	Zambia
Ethiopia	Myanmar	Zimbabwe
Gabon	Nicaragua	
Ghana	Nigeria	

FILED (18) 7% PLHCV

Azerbaijan	Mozambique
Bolivia	Namibia
Botswana	Nepal
Burundi	Paraguay
Georgia	Rwanda
Guatemala	Senegal
Haiti	Suriname
Honduras	Thailand
Kenya	Togo

▪ Vis-à-vis last update (Q4-20)


▪ Countries where either DAC 30mg or DAC 60mg have been sold indicated in **bold type**

[^] People living with Hepatitis C

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

[#] [MPP-BMS DAC licence agreement](#)

DAC 30mg or 60mg sales have occurred in **34** countries where MPP licensees have supplied more than **1.2 Million** treatments*, in which **67.8%** of PLHCV[^] reside in the licensed territory[#]



Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions


[^] People living with Hepatitis C

[#] [MPP-BMS DAC licence agreement](#)

*Note: 1 HCV treatment = 12 weeks therapy (3 packs)

3.6 million packs of DAC 30/60mg sold till March 2021


DAC 30/60mg Sales over the years by MPP Partners



TOP COUNTRY RECIPIENTS FOR DAC 30/60mg

DAC has been supplied in **34** countries as of March 2021 by MPP partners. While India constitutes 75% of the volume, 25% can be attributed to the countries shown here.

DAC sales in countries over the years (excluding India)



*Non-identified countries are a result of sales made through procurement agencies

** Others include countries in which fewer than 10,000 packs were sold

DAC/SOF: FORMULATION DEVELOPMENT TIMELINES



 Companies approved

***Note:** Each triangle represents a manufacturer and timelines represent date of filing*

1 MPP LICENSEE (MYLAN) HAS DEVELOPED DAC/SOF AND IS READY TO SUPPLY

Generic DAC/SOF has been filed in **18** countries, of which approval has been received in **11** countries
Filings have occurred where **34.9%** of PLHCV[^] reside in the licensed territory[#]

APPROVED (11) 29.7% PLHCV

Côte d'Ivoire

Nicaragua

Ethiopia

Nigeria

Ghana

Uganda

India

Zambia

Malawi

Zimbabwe

Myanmar

FILED (7) 5.2% PLHCV

Guyana

Suriname

Kenya

Tanzania

Namibia

Vietnam

Paraguay

▪ New filings and approvals in **green** vis-à-vis last update (Q4-20)


▪ Countries where DAC/SOF has been sold indicated in **bold type**

[^] People living with Hepatitis

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions


[#] [MPP-BMS DAC licence agreement](#)

MPP licensees have supplied more than **100,000** packs* of generic DAC/SOF across:
Cambodia, Ethiopia, India, Laos, Myanmar, Nigeria, South Africa, Uganda, Vietnam





THANK YOU



medicines
patent
pool